• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: TEOXANE SA RHA 4; HYALURONIC ACID DERMAL FILLER GEL

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

TEOXANE SA RHA 4; HYALURONIC ACID DERMAL FILLER GEL Back to Search Results
Lot Number TPUL-22492FL0
Medical Device Problem Code Improper or Incorrect Procedure or Method (2017)
Health Effect - Clinical Code Foreign Body Embolism (4439)
Date of Event 11/08/2023
Type of Reportable Event Serious Injury
Event or Problem Description
On november 14, 2023, the spanish subsidiary notified us of an adverse event following the use of teosyal rha 4 in a patient.A patient was injected on (b)(6) 2023, with 0.5 ml of teosyal rha 4 in the right cheek.The injection was done with a cannula using the retrotracing technique.According to the medical history of the patient, she was injected with teosyal rha 4 in 2018 in the zygomatic area and the nasolabial folds, without presenting with any adverse reactions.Immediately after the injection, on (b)(6) 2023, the patient experienced a mild vascular compromise, as she presented with delayed capillary refill in the injected area.On the same day, the injector administered 3 cycles of hyaluronidase (2000 iu in total) to the patient in one hour and a half.On november 14, 2023, we were informed that the patient had completely recovered.Thus, this case was considered closed.
 
Additional Manufacturer Narrative
Vascular complications are rare and serious side effects, although they are widely known and documented in the context of dermal filler injections.They are related to the accidental injection of the product inside a blood vessel, leading to its occlusion.The local deprivation of blood supply causes tissue anoxia.If enough hyaluronidase is injected on time, symptoms can be fully resolved without sequalae.If the vascular complication is not detected, diagnosed, and treated promptly, it can lead to skin necrosis.The risk of such adverse reactions is mentioned in the instructions for use of teosyal products.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
RHA 4
Common Device Name
HYALURONIC ACID DERMAL FILLER GEL
Manufacturer (Section D)
TEOXANE SA
rue de lyon 105
geneva, 1203
SZ  1203
Manufacturer (Section G)
TEOXANE SA
rue de lyon 105
geneva, 1203
SZ   1203
Manufacturer Contact
inés moreno pons
rue de lyon 105
geneva, 1203
SZ   1203
MDR Report Key18236089
Report Number3005975625-2023-00846
Device Sequence Number13097762
Product Code LMH
UDI-Device Identifier07640173232704
UDI-Public07640173232704
Combination Product (Y/N)N
Initial Reporter CountrySP
PMA/510(K) Number
P170002
Number of Events Summarized1
Summary Report (Y/N)N
Device Implanted Year2023
Serviced by Third Party (Y/N)N
Reporter Type Manufacturer
Report Source Foreign,Health Professional
Initial Reporter Occupation Physician
Type of Report Initial
Report Date (Section B) 11/30/2023
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Operator of Device Health Professional
Device Expiration Date12/31/2024
Device Lot NumberTPUL-22492FL0
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Type of Report(Section G)Thirty-Day
Initial Date Received by Manufacturer 11/14/2023
Initial Report FDA Received Date11/30/2023
Was Device Evaluated by Manufacturer? (Y/N) No
Date Device Manufactured12/31/2022
Is the Device Labeled for Single Use? (Y/N) Yes
Is This a Single-Use Device that was
Reprocessed and Reused on a Patient? (Y/N)
No
Usage of Device Initial
Patient Sequence Number1
Outcome Attributed to Adverse Event Other;
Patient Age46 YR
Patient SexFemale
-
-